

From: [Trials](#)
To: [Border, Scott](#); [Trials](#)
Cc: [Michael.Morin@lw.com](#); [Wong, Jovial](#); [David.Frazier@lw.com](#); [Roger.Chin@lw.com](#); [Inge.Osman@lw.com](#); [Ernest.Yakob@lw.com](#); [Michael.Seringhaus@lw.com](#); [Klein, Chuck](#)
Subject: RE: IPR2023-1444
Date: Wednesday, February 28, 2024 10:48:58 AM

Counsel,

From the Board –

The parties are authorized to file a Joint Motion to Terminate this IPR proceedings pursuant to 35 U.S.C. § 317 and 37 C.F.R. § 42.74, and a Joint Request that the Settlement Agreement be Treated as Business Confidential Information and Kept Separate under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c).

Regards,

Esther Goldschlager
Supervisory Paralegal Specialist
Patent Trial & Appeal Board
U.S. Patent & Trademark Office

From: Border, Scott <SBorder@winston.com>
Sent: Wednesday, February 28, 2024 8:46 AM
To: Trials <Trials@USPTO.GOV>
Cc: Michael.Morin@lw.com; Wong, Jovial <JWong@winston.com>; David.Frazier@lw.com; Roger.Chin@lw.com; Inge.Osman@lw.com; Ernest.Yakob@lw.com; Michael.Seringhaus@lw.com; Klein, Chuck <CKlein@winston.com>
Subject: IPR2023-1444

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Your Honors,

Petitioner Biocon Biologics Inc. and Patent Owner Janssen Biotech Inc. have reached an agreement to settle their disputes in IPR2023-1444. The Parties, therefore, seek authorization to file a Joint Motion to Terminate this IPR proceedings pursuant to 35 U.S.C. § 317 and 37 C.F.R. § 42.74, and a Joint Request that the Settlement Agreement be Treated as Business Confidential Information and Kept Separate under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c).

Sincerely,
Scott Border
Counsel for Petitioner

Scott Border
Partner

Winston & Strawn LLP
1901 L Street, N.W.
Washington, D.C. 20036-3506

D: +1 202-282-5054

M: +1 703-899-4136

[Bio](#) | [VCard](#) | [Email](#) | [winston.com](#)



The contents of this message may be privileged and confidential. If this message has been received in error, please delete it without reading it. Your receipt of this message is not intended to waive any applicable privilege. Please do not disseminate this message without the permission of the author. Any tax advice contained in this email was not intended to be used, and cannot be used, by you (or any other taxpayer) to avoid penalties under applicable tax laws and regulations.